Mild Guillain-Barré syndrome

Area of Science:

• Neurology
• Clinical Medicine
• Immunology

Background:

• Guillain-Barré syndrome (GBS) presents unpredictability, complicating early management decisions.
• Existing GBS treatment trials often exclude milder cases, limiting knowledge on their care.
• Identifying predictors for mild GBS is crucial for appropriate patient management.

Purpose of the Study:

• To estimate the frequency of mild GBS cases where patients can still walk.
• To identify clinical or electrophysiologic features predicting a mild GBS course.
• To inform treatment strategies for GBS patients with preserved ambulation.

Main Methods:

• A registry of GBS patients was maintained at a community teaching hospital from 1992 to 2000.
• Analysis included 254 GBS cases, focusing on the 12 (4.7%) who could walk throughout their illness.
• Clinical data, preceding infections, symptoms, cerebrospinal fluid, and electrophysiologic findings were reviewed.

Main Results:

• Twelve patients (4.7%) maintained the ability to walk; eight received plasmapheresis or IVIg, four were observed.
• Mild GBS cases reached nadir weakness around day 8, similar to severe cases.
• No significant clinical or electrophysiologic differences distinguished mild from severe GBS or treated from untreated mild cases.

Conclusions:

• Mild GBS cases progress similarly to severe ones, reaching maximal weakness around day 8.
• Observation until day 8 is recommended for ambulatory GBS patients to rule out progression.
• Treatment may be unnecessary for GBS patients who can walk during the second week of illness.